And Joe, I’ll say one thing about stupid. If I had an investor, plus a lawyer with SEC experience, we would never have heard of the ridiculous Hema that makes absolutely nothing, or the weak Emmaus unless the deal didn’t completely harm GNBT shareholders, or even consider the embarrassing Global Medical Direct, never mind the WILDLY toxic Veneto, or the likewise companies tied to Veneto’s legacy business-MediSource or Pantheon. None of that would’ve occurred. Because wasting shares and money is stupid. And I’d widen the shareholder base. Jmho.

Smart is smart. Ii-Key peptide vaccines. Yes, Sars-Covid, or multiple combination approaches including CAR-T. Multiple peptide approaches, as you once told me is a stupid idea - oh boy. Much credit to EvH, Dr Mittendorf, Dr Humphrey’s as nothing peer review happened past Mark Fletcher as CEO. No studies for Oral-Lyn or AE37.

Don’t criticize other companies. Show a single area of your success. Let’s go.